SLC5A6

Across TCGA pan-cancer cohorts, SLC5A6 Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated SLC5A6 data layer compared with 25 for mass-spec protein and 7 for mass-spec protein.

The strongest signal is observed in kidney renal papillary cell carcinoma (KIRP), where higher SLC5A6 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated SLC5A6 expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

KIRP, GBM, and SARC are the cancer types where SLC5A6 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
KIRP	OS	Median	All	0.094	0.690	<.001	27	view →
GBM	OS	Median	All	0.079	0.415	.003	9	view →
SARC	DFS	Median	All	0.179	0.612	.024	6	view →
LUAD	OS	Median	II,III,IV	0.090	0.677	<.001	6	view →
UCEC	DFS	Median	All	1.000	0.629	.029	4	view →
ACC	DFS	Median	All	0.195	0.748	.003	3	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

SLC5A6–KIRP (OS)

Open the KIRP breakdown →